Goldan Keith A.

Chief Financial OfficerSyndax Pharmaceuticals Inc (SNDX) · full profile →Form 4 · filed Jul 18, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$12K
Net Open-Market Flow
-$12K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jul 16, 2025Sell(S)1K$9.29$12K92K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-25-096948) within minutes of acceptance. Every field above traces to the original document. Verify it directly: